AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)

计划入组 1,250 人 · 首次发布于 2021 年 3 月 19 日

EVOO and Metabolic Liver Health in MASLD

计划入组 60 人 · 首次发布于 2026 年 2 月 17 日

Korean Health Screening-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Registry

计划入组 6,000 人 · 首次发布于 2025 年 2 月 25 日

liver disease program

undisclosed drug (fibrotic liver disease/NASH), Engitix/Takeda

MSDC-3G

INSTITUTE OF LIVER AND BILIARY SCIENCES

India

Swedish Institute For Infectious Disease Control

MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH INC.

Papua New Guinea

Icosabutate Shows Promising Anti-Fibrotic Results in Phase 2b MASH Trial

Stravitz–Sanyal Liver Institute Opens $30 Million Clinical Research Imaging Center to Accelerate Liver and Metabolic Disease Drug Development

Semaglutide 2.4 mg Shows Promise in MASH Treatment: Phase 3 ESSENCE Trial Results